Immunology Research Program

免疫学研究计划

• 批准号: 10534179
• 负责人: Jonathan S. Serody
• 金额: $ 4.6万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-06-01 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10534179
• 关键词: Acute; Acute Graft Versus Host Disease; Adaptive Immune System; Adoptive Cell Transfers; Affect; Allogenic; Antigens; B-Lymphocytes; Biology; Breast; CAR T cell therapy; CD276 gene; Cancer Center; Cancer Center Support Grant; Cancer Vaccines; Catchment Area; Cell Therapy; Cells; Clinical; Colorectal; Colorectal Cancer; Communities; Community Outreach; Development; Direct Costs; Disease; Doctor of Philosophy; Education; Evaluation; Faculty; Foundations; Funding; Genetic; Genomic approach; Genomics; Glioblastoma; Grant; Growth; Immune; Immune response; Immune system; Immunogenomics; Immunologic Receptors; Immunology; Immunotherapeutic agent; Immunotherapy; Inflammatory; Innate Immune System; Joints; Journals; Leadership; Lymphocyte; Lymphoid Cell; Lymphoma; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Mediating; Medicine; Mentors; Mentorship; Microbiology; Multiple Myeloma; Myeloid-derived suppressor cells; Nanodelivery; Neuroblastoma; Obesity; Outcome; Ovarian; Pancreas; Paper; Pathogenesis; Pathway interactions; Patient-Focused Outcomes; Patients; Play; Population; Postdoctoral Fellow; Process; Property; Publications; Regulatory Pathway; Regulatory T-Lymphocyte; Relapse; Research; Research Personnel; Resistance; Risk Factors; Role; Solid Neoplasm; Stem cell transplant; Strategic Planning; Students; T cell therapy; T-Lymphocyte; TNFRSF8 gene; Technology; The Cancer Genome Atlas; Training; Training and Education; Translating; Translational Research; Tumor Immunity; Tumor Subtype; Tumor Suppression; United States National Institutes of Health; Work; biological systems; cancer cell; cancer therapy; cancer vaccination; carcinogenesis; career; checkpoint therapy; chimeric antigen receptor T cells; chronic graft versus host disease; cigarette smoke; community engagement; cytokine; graft vs host disease; graft vs leukemia effect; gut microbiota; immune function; improved outcome; informatics tool; innate immune function; innovation; malignant breast neoplasm; medical schools; member; microbiome; microbiota; neoplasm immunotherapy; new therapeutic target; novel; novel strategies; outreach; peer; preclinical study; professor; programs; recruit; response; targeted treatment; translational immunology; triple-negative invasive breast carcinoma; tumor; tumor immunology; tumor microenvironment; tumorigenesis; tumorigenic; undergraduate student; virus related cancer

ABSTRACT: IMMUNOLOGY PROGRAM The Immunology Program (IMM) is devoted to enhancing our understanding of the function of the innate and adaptive immune system in the pathogenesis of malignant disease. There are four specific aims: (1) Elucidate new roles for innate immune receptors and the microbiome in carcinogenesis; (2) Uncover novel functions of diverse immune cells and pathways in the tumor microenvironment; (3) Develop novel approaches to use immunotherapy to treat patients with cancer; (4) Discover new targets for improving the outcome of patients with malignant disease undergoing allogeneic stem cell transplantation (allo-SCT). There are 24 program members from six different departments at UNC School of Medicine. Members have $13.2M (direct costs) cancer-related funding including; $2.8M in direct costs from NCI and $6.8M in in direct other peer and other NIH. NCI funding has increased 145% since the last submission. Highlights of the program include discoveries of new roles of innate immune receptors in colorectal cancer; importance of microbiota on cancer-relevant immune cell populations; a comprehensive immunogenomic characterization of the tumor microenvironment for TCGA and critical roles for T follicular helper and B cells during checkpoint inhibitor therapy in breast cancer. Significant translational findings include the new use of antigens expressed on solid tumors as targets for chimeric antigen receptor modified T cell therapy (CAR T) including B7-H3 for pancreatic cancer and glioblastoma, and CD138 for multiple myeloma. IMM is led by Jenny Ting PhD, William Rand Kenan Professor of Genetics, Microbiology-Immunology (M-I) and Director of the Translational Immunology Center who is a world’s expert on innate immune receptors, and Jonathan Serody MD, Elizabeth Thomas Professor of Medicine, M-I and the Associate Director for Translational Sciences in the Cancer Center, who is an expert on the biology of GVHD, tumor vaccines and the tumor microenvironment. IMM leadership works closely with CR to translate findings from IMM. These include the evaluation of CD30-specific CART T cells in the treatment of CD30-expressing lymphomas, B7-H3-specific CAR T cells in relapsed ovarian cancer and GD2-specific CAR T cells in neuroblastoma. Six outstanding faculty members have been recruited since the last grant submission. IMM has a strong publication record with 359 papers; 18% intra-programmatic, 39% inter-programmatic publications and 33% of the papers were in journals with an impact factor > 10. IMM has a strong record of training with two training grants focused on tumor immunology or immunotherapy. Research within IMM has been significantly informed by the Office of Outreach and Community Engagement with an emphasis on cancers in the catchment area, including breast, colorectal, pancreatic cancers and multiple myeloma.

摘要：免疫学计划 免疫学计划（IMM）致力于增强我们对先天性功能的理解和 恶性疾病发病机理中的自适应免疫系统。有四个具体目标： （1）阐明了先天免疫受体的新作用和微生物组在癌变中； （2）发现潜水免疫细胞和途径在肿瘤微环境中的新功能； （3）开发了使用免疫疗法治疗癌症患者的新型方法； （4）发现新的靶标，以改善患有恶性疾病患者的结果 同种异体干细胞移植（Allo-SCT）。 UNC医学院的六个不同部门有24个计划成员。成员有 1320万美元（直接费用）与癌症有关的资金，包括； NCI的直接成本为280万美元，直接成本为680万美元 其他同伴和其他NIH。自上次提交以来，NCI资金已增加了145％。亮点 计划包括发现天生免疫受体在结直肠癌中的新作用；重要性 与癌症相关的免疫细胞种群的微生物群；全面的免疫基因组表征 检查点期间TCGA的肿瘤微环境和T卵泡辅助器和B细胞的关键作用 乳腺癌的抑制剂疗法。重大的翻译发现包括表达的抗原的新使用 在实体瘤作为嵌合抗原受体改性T细胞疗法（CAR T）的靶标上，包括B7-H3的 胰腺癌和胶质母细胞瘤，以及用于多发性骨髓瘤的CD138。 IMM由William Rand Kenan遗传学教授，微生物 - 免疫学（M-I）领导 以及转化免疫学中心的主任，他是世界先天免疫接收者的专家， 乔纳森·塞迪（Jonathan Serody）医学博士，伊丽莎白·托马斯（Elizabeth Thomas）医学教授，M-I和副主任 癌症中心的转化科学，他是GVHD生物学，肿瘤疫苗和 肿瘤微环境。 IMM领导力与CR紧密合作，以转化IMM的发现。这些包括 CD30特异性推车T细胞在表达CD30的淋巴瘤治疗中的评估，B7-H3特异性 中继卵巢癌和神经母细胞瘤中GD2特异性CAR T细胞中的CAR T细胞。六个杰出 自上次赠款提交以来，已招募教职员工。 IMM有很强的出版记录 359篇论文； 18％的截图，39％的前编程出版物和33％的论文 影响因素> 10的期刊。IMM具有较强的培训记录，两项培训补助金的重点是 肿瘤免疫学或免疫疗法。 IMM内部的研究已由 推广和社区参与，重点是包括乳房在内的集水区的癌症 结直肠癌，胰腺癌和多发性骨髓瘤。